Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6846

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Interventions: Azetukalner; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 12
States / cities: Torrance, California • New Haven, Connecticut • Ft. Pierce, Florida + 8 more

Conditions: Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight
Interventions: PF-08653945, PF-08653944, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 53
States / cities: Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more

Conditions: Chronic Kidney Disease With High Proteinuria
Interventions: Zibotentan/Dapagliflozin, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 64
States / cities: Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more

Conditions: Major Depressive Disorder
Interventions: Azetukalner; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 69
States / cities: Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more

Conditions: Fabry Disease
Interventions: Venglustat (GZ402671), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more

Conditions: Pain
Interventions: neurostimulation system; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2035
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 60 more

Conditions: Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Interventions: GB-4362, enfortumab vedotin (EV), Pembrolizumab; Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Orlando, Florida + 7 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 59
States / cities: Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more

Conditions: Ovarian Cancer
Interventions: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: La Jolla, California • Solvang, California • Gainesville, Florida + 28 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions: Axonics SNM System; Device
Lead sponsor: Axonics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

An Open-Label Study of Azetukalner in Major Depressive Disorder

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Sacral Neuromodulation for Male Overactive Bladder (MOAB)